91Ӱ

Award

Toker recognized for ‘seminal contributions’ to lipid biology

He’s won the 2022 91ӰAvanti Award in Lipids
Courtney Chandler
Dec. 7, 2021

always has been interested in science, and he recalls many days spent at the Natural History Museum in London, where he grew up. Yet it wasn’t until his postdoctoral years spent under the mentorship of that he decided to make research his career.

Toker-445x473.jpg
Alex Toker

“I just had kind of an epiphany and decided this is what I want to do for the rest of my life,” Toker said. “I loved basic science and discovering things.”

In 1988, Cantley won the 91Ӱ and Molecular Biology’s Avanti Award in Lipids. Toker, now a professor at Harvard Medical School and editor-in-chief of the Journal of Biological Chemistry, will receive the same award in 2022. Toker is being recognized for his work on lipid signaling and particularly his studies on phosphatidylinositol 3-OH kinase, or PI3K, and serine/threonine kinase AKT signaling in cancer.

, a distinguished professor and chair in chemistry at Texas A&M University and winner of the 2019 Avanti Award, wrote in his nomination letter that Toker deserved the award for his “seminal contributions to the lipid field” and “steadfast professionalism.” Toker received word about the award while on vacation in New Hampshire.

“I was just so proud and ecstatic and filled with a sense of achievement and recognition by my peers,” Toker said. “It really is a culmination of 20-plus years of running a laboratory, and, considering the past recipients, it is truly humbling.”

The discovery aspect of research still drives him, and he enjoys the independence and creativity scientific research can bring. He is also passionate about mentoring.

“The greatest source of joy and pride and the most satisfying aspect of my career is really the training of the scientists and students that I’ve had in my laboratory,” he said.

Toker credits his family, trainees, mentors and colleagues with helping get to where he is today.

Pathways past and future

Alex Toker’s research focuses on understanding how intracellular signaling pathways affect cancer cell behavior. During his postdoc work, he identified that a protein kinase called Akt, also known as protein kinase B, or PKB, was activated by lipid products of the PI3K pathway, thus linking the two signaling pathways.

The two pathways, together with the mammalian target of rapamycin, or mTOR, pathway, collectively control cellular metabolism, proliferation and growth, and survival. All are dysregulated in certain types of cancer.

In his award talk, Toker plans to start at his seminal discovery linking lipid mediators with specific signaling and move through his subsequent work characterizing Akt and other pathways in the cell and in cancer. He also will focus on where he thinks the field is going and ongoing studies in his lab aimed at designing therapeutic interventions targeting the pathway.

Enjoy reading 91ӰToday?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a careers columnist for 91ӰToday.

Get the latest from 91ӰToday

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Fliesler wins scientific and ethical awards
Member News

Fliesler wins scientific and ethical awards

July 21, 2025

He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

91Ӱmembers recognized as Allen investigators
Member News

91Ӱmembers recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, 91Ӱeducators say
Advice

AI can be an asset, 91Ӱeducators say

July 9, 2025

Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.

91Ӱundergraduate education programs foster tomorrow’s scientific minds
Feature

91Ӱundergraduate education programs foster tomorrow’s scientific minds

July 8, 2025

Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.